Cannabis and Depression: Early Signals, Limited Evidence, and Important Risks
Interest in cannabis as a possible treatment for depression has grown, but the evidence remains mixed and limited. Studies have examined individual cannabinoids in animals, short-term symptom changes reported by cannabis users, and broader links between cannabis use and mental health. These forms of evidence cannot establish that cannabis treats clinical depression.
Depression is a serious disorder involving persistent low mood or loss of interest, often accompanied by changes in sleep, appetite, energy, concentration, or feelings of self-worth. Established treatments include psychotherapy and antidepressant medication, although not every patient benefits from a first treatment and side effects can be a concern. That has led researchers to investigate alternatives, including cannabis-derived compounds.
Some early findings have come from laboratory research. A 2010 study, published in Pharmacology, Biochemistry and Behavior, tested THC and several other cannabinoids in mice using behavioral assays commonly used to screen for antidepressant-like activity. THC and cannabichromene (CBC) produced effects in some tests, while cannabidiol (CBD) showed an effect at a much higher dose. Cannabigerol (CBG), however, did not produce an antidepressant-like effect in the forced-swim test at the doses examined. These results are preclinical: they do not demonstrate that cannabis or any of these compounds is an effective treatment for depression in people.
Human evidence has also produced encouraging but highly qualified results. In a 2020 observational study, researchers analyzed 5,876 self-administration sessions recorded by 1,819 people using the ReleafApp. Participants reported an average short-term reduction in depression-related symptom intensity after using cannabis flower, and 95.8% of sessions were followed by some reported relief. THC levels were more strongly associated with immediate symptom changes than CBD levels.
That study measured users’ experiences in real time; it was not a randomized clinical trial. Participants chose whether, when, and how much cannabis to use, and there was no placebo comparison or evidence that the reported relief lasted beyond the immediate period after consumption. Some users also reported effects that could worsen depression-related problems, including feeling unmotivated. Short-term symptom relief should therefore not be equated with treatment of major depressive disorder.
A larger review provides a more cautious interpretation. The 2019 systematic review and meta-analysis in The Lancet Psychiatry included 83 eligible studies, including 40 randomized controlled trials and 3,067 participants across several psychiatric conditions. Of the studies addressing depression, the review found scarce evidence that medicinal cannabinoids improved depressive disorders or symptoms. The authors also reported more adverse events and withdrawals because of adverse events among people receiving cannabinoids than among those receiving placebo. The review did not provide moderate evidence that medicinal cannabis treats depression, as the potentially suggested.
Other research has explored possible biological mechanisms. In a 2020 mouse study, terpineol showed antidepressant-like effects in an inflammatory model of depression, with results implicating cannabinoid and dopamine D2 receptors. Terpineol is a plant-derived terpene, but findings from mice exposed to an experimental inflammatory challenge cannot be directly translated into a recommendation for cannabis use in people with depression.
The risks also deserve attention. The Centers for Disease Control and Prevention’s overview of cannabis and mental health notes associations between cannabis use and depression, anxiety, suicidal thoughts, suicide attempts, and suicide. Associations do not by themselves prove that cannabis causes these outcomes; depression, substance use, genetics, stress, and other factors can influence one another. Nevertheless, a 2024 systematic review found that cannabis use was associated with more depressive symptoms and a less favorable course or prognosis for mood disorders.
Overall, cannabis research has generated hypotheses rather than established a treatment. Animal experiments and self-reported short-term relief may justify further study, but they do not show that cannabis is safe or effective for sustained treatment of depression. Anyone experiencing persistent depressive symptoms should discuss evidence-based options with a qualified health professional rather than replacing prescribed care with cannabis. People experiencing thoughts of suicide or immediate danger should seek urgent help through emergency services or a crisis hotline.
